Treatment strategies for giant pituitary adenomas in the era of endoscopic transsphenoidal surgery: a multicenter series

Alexander Micko, Matthew S. Agam, Andrew Brunswick, Ben A. Strickland, Martin J. Rutkowski, John D. Carmichael, Mark S. Shiroishi, Gabriel Zada, Engelbert Knosp, Stefan Wolfsberger

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

OBJECTIVE Given the anatomical complexity and frequently invasive growth of giant pituitary adenomas (GPAs), individually tailored approaches are required. The aim of this study was to assess the treatment strategies and outcomes in a large multicenter series of GPAs in the era of endoscopic transsphenoidal surgery (ETS). METHODS This was a retrospective case-control series of 64 patients with GPAs treated at two tertiary care centers by surgeons with experience in ETS. GPAs were defined by a maximum diameter of ≥ 4 cm and a volume of ≥ 10 cm3 on preoperative isovoxel contrast-enhanced MRI. RESULTS The primary operation was ETS in all cases. Overall gross-total resection rates were 64% in round GPAs, 46% in dumbbell-shaped GPAs, and 8% in multilobular GPAs (p < 0.001). Postoperative outcomes were further stratified into two groups based on extent of resection: group A (gross-total resection or partial resection with intracavernous remnant; 21/64, 33%) and group B (partial resection with intracranial remnant; 43/64, 67%). Growth patterns of GPAs were mostly round (11/14, 79%) in group A and multilobular (33/37, 89%) in group B. In group A, no patients required a second operation, and 2/21 (9%) were treated with adjuvant radiosurgery. In group B, early transcranial reoperation was required in 6/43 (14%) cases due to hemorrhagic transformation of remnants. For the remaining group B patients with remnants, 5/43 (12%) underwent transcranial surgery and 12/43 (28%) underwent delayed second ETS. There were no deaths in this series. Severe complications included stroke (6%), meningitis (6%), hydrocephalus requiring shunting (6%), and loss or distinct worsening of vision (3%). At follow-up (mean 3 years, range 0.5-16 years), stable disease was achieved in 91% of cases. CONCLUSIONS ETS as a primary treatment modality to relieve mass effect in GPAs and extent of resection are dependent on GPA morphology. The pattern of residual pituitary adenoma guides further treatment strategies, including early transcranial reoperation, delayed endoscopic transsphenoidal/transcranial reoperation, and adjuvant radiosurgery.

Original languageEnglish (US)
Pages (from-to)776-785
Number of pages10
JournalJournal of neurosurgery
Volume136
Issue number3
DOIs
StatePublished - Mar 2022
Externally publishedYes

Keywords

  • endoscopic
  • giant pituitary adenoma
  • invasive
  • outcome
  • pituitary surgery

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Treatment strategies for giant pituitary adenomas in the era of endoscopic transsphenoidal surgery: a multicenter series'. Together they form a unique fingerprint.

Cite this